2006 Annual Meeting | Headache Therapy

Date Thursday 05/03/07

Time 07:00 PM - 09:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Therapy Program

Director(s) Joel R. Saper, MD, FAAN

Topic(s)

Learning Objectives Upon Completion:
Participants should be able to better understand current therapy for selected primary headache topics, understand the faculty's perspective regarding treatment, and be able to better treat patients with primary headache.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
07:00 PM - 07:30 PM		Migraine Therapy: Update and Review Stephen D. Silberstein, MD, FAAN
07:00 PM - 09:00 PM		Refreshments
07:30 PM - 08:00 PM		Treatment of Cluster Headache and Trigeminal Autonomic Cephalgias Peter Goadsby, MD, PhD, FRS
08:00 PM - 08:30 PM		Clinical Strategies for Intractable Headaches and Treatment of Medication-Overuse Headache Joel R. Saper, MD, FAAN
08:30 PM - 09:00 PM		Relevant Case Discussions and Interaction With the Audience

Faculty Disclosures
Joel R. Saper, MD, FAAN	No disclosure on file
Stephen D. Silberstein, MD, FAAN	Dr. Silberstein has received publishing royalties from a publication relating to health care.
Peter Goadsby, MD, PhD, FRS	Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli-Lilly. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aurene. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vial. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon Biopharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. The institution of Dr. Goadsby has received research support from Kallyope. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to AAN interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to AAN interests or activities. Dr. Goadsby has a non-compensated relationship as a Executive roles with American Headache Society that is relevant to AAN interests or activities.

��ɫ��

��ɫ��